A review of romiplostim mechanism of action and clinical applicability
JB Bussel, G Soff, A Balduzzi, N Cooper… - Drug design …, 2021 - Taylor & Francis
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy,
autoimmune disease, bone marrow disorders, pathologic conditions associated with …
autoimmune disease, bone marrow disorders, pathologic conditions associated with …
Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
JD Grainger, T Kühne, J Hippenmeyer, N Cooper - Annals of Hematology, 2021 - Springer
Immune thrombocytopenia (ITP) is a disease of heterogenous origin characterized by low
platelet counts and an increased bleeding tendency. Three disease phases have been …
platelet counts and an increased bleeding tendency. Three disease phases have been …
The role of romiplostim for pediatric patients with immune thrombocytopenia
H Al-Samkari, RF Grace… - Therapeutic advances in …, 2020 - journals.sagepub.com
The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors used
to treat immune thrombocytopenia (ITP) in children and adults. Romiplostim is a peptide …
to treat immune thrombocytopenia (ITP) in children and adults. Romiplostim is a peptide …
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia
ML Lozano, B Godeau, J Grainger… - Expert Review of …, 2020 - Taylor & Francis
Introduction: Three distinct phases are recognized in immune thrombocytopenia (ITP): newly
diagnosed (≤ 3 months after diagnosis), persistent (> 3–12 months after diagnosis), and …
diagnosed (≤ 3 months after diagnosis), persistent (> 3–12 months after diagnosis), and …
[HTML][HTML] Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia
DJ Kuter, MD Tarantino, T Lawrence - Blood Reviews, 2021 - Elsevier
The fundamental treatment goal for patients with immune thrombocytopenia (ITP) is reduced
or ameliorated bleeding. Although various treatment options exist for the management of …
or ameliorated bleeding. Although various treatment options exist for the management of …
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry
C Bowers, DT Mytych, T Lawrence, K Wang… - Blood …, 2021 - ashpublications.org
Abstract Development of first-generation thrombopoietins (TPOs) was halted due to
antibodies that neutralized endogenous TPO, causing protracted thrombocytopenia in some …
antibodies that neutralized endogenous TPO, causing protracted thrombocytopenia in some …